All In Biotech

Drug Trial Radar · NCT02916056

2-Year Extension Study of Azeliragon in Subjects With Alzheimer's Disease (STEADFAST Extension)

Open Label Extension Study for Continued Safety and Efficacy Evaluation of Azeliragon in Patients With Mild Alzheimer's Disease

Last checked: Nov 19, 2026Latest source record: Jun 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

297

Actual

Start

Dec 2016

Primary completion

Jun 1, 2018

Study completion Jun 1, 2018

Sponsor

Lead sponsor
vTv TherapeuticsIndustry
Sponsor type
Industry
First posted
Sep 27, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label extension study in patients with mild Alzheimer's disease who have completed participation in the azeliragon Phase 3 (STEADFAST) trial. Patients will receive azeliragon 5 mg/day for up to 2 years.

Conditions

  • Alzheimer's Disease

Interventions

  • Azeliragon 5mgDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects With at Least One Treatment-Emergent Adverse EventTime frame: up to 18 months

Locations

71 sites in 2 countries. Site status is shown where the registry gives one.

  • Site not named

    Phoenix, Arizona

  • Site not named

    Phoenix, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Bellflower, California

  • Site not named

    Costa Mesa, California

  • Site not named

    Fullerton, California

  • Site not named

    Glendale, California

  • Site not named

    Imperial, California

  • Site not named

    Irvine, California

  • Site not named

    Laguna Hills, California

  • Site not named

    Long Beach, California

  • Site not named

    Riverside, California

  • Site not named

    San Bernardino, California

  • Site not named

    Santa Ana, California

  • Site not named

    Atlantis, Florida

  • Site not named

    Delray Beach, Florida

  • Site not named

    Hallandale, Florida

  • Site not named

    Hialeah, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Lake Worth, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Miami Beach, Florida

  • Site not named

    Miami Lakes, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Sarasota, Florida

  • Site not named

    Sunrise, Florida

  • Site not named

    The Villages, Florida

  • Site not named

    Columbus, Georgia

  • Site not named

    Chicago, Illinois

  • Site not named

    Fairway, Kansas

  • Site not named

    Lexington, Kentucky

  • Site not named

    Baltimore, Maryland

  • Site not named

    Newton, Massachusetts

  • Site not named

    Plymouth, Massachusetts

  • Site not named

    Quincy, Massachusetts

  • Site not named

    Hattiesburg, Mississippi

  • Site not named

    Creve Coeur, Missouri

  • Site not named

    St Louis, Missouri

  • Site not named

    Princeton, New Jersey

Showing 40 of 71 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.